A coronary aneurysm (CA) can occur in sirolimus-eluting stent (SES)-implanted coronary lesions. Although several possible mechanisms have been suggested, the precise pathogenesis of a CA in SES-implanted lesions is still unknown. We report a patient with Churg-Strauss syndrome who underwent successful percutaneous coronary intervention with SES and then experienced a CA in an SES-implanted coronary lesion. We describe the CA characteristics through the use of coronary angiography, coronary 64-multidetector computed tomography, and intravascular ultrasound and discuss the etiological factors for the CA in this patient. (Korean Circ J 2011;41:559-562)
Introduction
The sirolimus-eluting stent (SES) has provided excellent clinical outcomes by significantly reducing the number of major adverse cardiac events. 1)2) However, SESs can cause unexpected vascular complications, such as stent thrombosis 3) and a coronary aneurysm (CA) 4) at SES-implanted coronary lesions. Furthermore, systemic necrotizing vasculitis, such as Churg-Strauss syndrome (CSS), can involve the native coronary artery in the form of coronary ectasia or an aneurysm. Although the precise mechanisms of CA development at SESimplanted coronary lesions are still unclear, both SESs and CSS can precipitate a CA by weakening the coronary vessel walls. 5) We report a case of CA at an SES-implanted coronary lesion in a patient with CSS and describe the lesion features using several imaging modalities.
Case
A 43 year old man presented with ongoing resting chest pain for the past 2 hours. He had been diagnosed with CSS at another general hospital 4 months earlier. He met the diagnostic criteria for CSS 6) with asthma, allergic sinusitis, hypereosinophilia, and systemic vasculitis of the skin, and was receiving oral prednisone and cyclophosphamide. He had no other coronary risk factors. An initial electrocardiogram showed an ST-segment elevation from the V2 to V6 leads. Diagnostic coronary angiography (CAG) revealed a total occlusion of the mid-left anterior descending (LAD) coronary artery (Fig. 1A) . After a manual intracoronary aspiration thrombectomy (Export; Medtronic, Santa Rosa, CA, USA) at the mid LAD lesion (Fig. 1B) , a subsequent CAG revealed diffuse irregular and significant stenosis from the mid to distal LAD with restoration of thrombolysis and myocardial infarction grade 3 (Fig. 1C) . A successful primary percutaneous coronary intervention (PCI) was performed with 2 SESs (Cypher; Cordis Johnson and Johnson, Warren, NJ, USA) placed from the mid to proximal LAD (diameter×length: 3.0×33 mm, and 3.5×23 mm) at a pressure of 18 atm ( Fig. 1D and E) . The final CAG showed good angiographic results at the LAD lesion (Fig. 1F) . The patient was discharged on the third day with no cardiac symptoms and was prescribed 75 mg clopidogrel and 100 mg aspirin daily.
A follow-up CAG was performed at 14 months after the primary PCI. We substituted coronary 64-multidetector computed tomography (MDCT) for conventional CAG. Three-dimensional (3-D) surface reconstruction images from the coronary 64-MDCT revealed good positioning of the two overlapping SESs with no neointimal hyperplasia ( Fig. 2A) . Additionally, a volume-rendering image on coronary 64-MDCT showed no neointimal hyperplasia or stent malapposition ( Fig. 2B ) compared to the final result.
He was readmitted to our hospital 39 months later with atypical chest discomfort for the past 10 days. We performed a follow-up coronary 64-MDCT and CAG. The follow-up 3-D surface reconstruction view on coronary 64-MDCT disclosed a fusiform like diffuse enlargement of the LAD at the SES-implanted lesion. (Fig. 2C) , and the volume-rendering image on coronary 64-MDCT showed a crescent-like shape to contrast dye filling in around the stent border (Fig.  2D) . A follow-up CAG showed a diffuse multiple conglomerate contrast filling in along the stent border without in-stent restenosis (Fig. 2E ). An intravascular ultrasound revealed significant gaps between the SES struts and the vessel wall and an enlargement of the external elastic membrane with a maximum diameter of 6.59 mm in the proximal portion, 6.42 mm in the mid portion, and 6.82 mm in the distal portion (Fig. 3) . We then had the patient undergo an exercise treadmill test to confirm myocardial ischemia; however, the result was negative. Finally, we decided to treat the patient with medical therapy. The patient is under careful observation and is receiving dual antiplatelet therapy.
Discussion
A CA is defined as a segment with a diameter greater than 1.5 times the normal adjacent artery segment and can be classified as fusiform or saccular. 7) A CA at an SES-implanted site accompanies stent malapposition. Although the precise mechanism of a CA at an SES-implanted site is unclear, several possible mechanisms, including acute vessel damage during coronary intervention, localized hypersensitivity to the polymer, and vascular remodeling as a result of high drug concentrations have been postulated. 8) The CAG and coronary 64-MDCT findings in the present case suggested that the CA development may have been related to hypersensitivity to the SES at the contact sites between the vessel wall and the stent surface. Because we did not find a CA on the baseline CAG, the SES may have played an important role in CA development. In contrast, vascular inflammatory responses occurring in patients with CSS may not affect the development of a CA, because no elevated eosinophils were found on the complete blood count, and serum C-reactive protein was not elevated in this patient. Only one case of acute myocardial infarction has been reported due to plaque rupture in a patient with CSS. 9) Furthermore, previous studies indicate that coronary artery involvement in patients with CSS is uncommon. Sirolimus has an anti-inflammatory property that inhibits the local inflammatory response at the stent-implanted lesion site. Sirolimus may not only inhibit neointimal growth but also endothelial depletion at the stent-implanted site. Endothelial depletion caused by sirolimus may trigger the development of a CA secondary to smooth muscle cell degeneration.
The natural course and the appropriate treatment for a CA remain uncertain. However, it is certain that patients with a CA need prolonged aspirin and dual antiplatelet therapy. Surgical treatment is indicated for patients with a significant CA obstructive lesion or evidence of embolization leading to myocardial ischemia and progressive enlargement of the saccular type of CA leading to rupture. Because a CA at an SES-implanted coronary lesion may have a benign clinical course, it is very important to choose the optimal treatment plan carefully.
However, it has not been demonstrated that localized exaggerated hypersensitivity due to sirolimus, polymers, or stent metal triggers the development of a CA. The development of the CA in this patient seemed to be due to more complex pathogenesis than expected, so an in-depth investigation would confirm the association between localized hypersensitivity vasculitis and incomplete endothelization. 
